Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Neuromultivit · 1 trial · 1 indication
Self reported pain intensity over the last 24 hours. The amount of pain is marked on a horizontal line at a certain point which reflects pain perception best: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).
| Arm | Type | Description |
|---|---|---|
| Neuromultivit +Voltaren+Sirdalud | EXPERIMENTAL | Neuromultivit 2ml i.m. once a day for 7 days, then 2 ml i.m. one time every other day for 10 days. Voltaren 100mg per os once a day for 20 days. Sirdalud 2 mg per os three times a day for 20 days. |
| Voltaren+Sirdalud alone | ACTIVE_COMPARATOR | Voltaren 100mg per os once a day for 20 days Sirdalud 2 mg per os three times a day for 20 days |
| Name | Type | Description |
|---|---|---|
| Neuromultivit | DRUG | - |
| Voltaren | DRUG | - |
| Sirdalud | DRUG | - |
Inclusion Criteria: * diagnosed vertebrogenic radiculopathy L5, S1 * radicular pain syndrome * changes in the low back CT and MRI scans * minimum 40 mm intensity of spontaneous back pain, rated on the VA scale * 1 month exacerbation phase; nonuse of any B-group vitamins before the trial * negative ...
Neuromultivit is an investigational small molecule being studied for the treatment of vertebrogenic radiculopathy affecting the L5 and S1 nerve roots. It is in Phase 3 clinical development for this neurological condition.
Neuromultivit is being developed by Bausch Health Companies Inc. (NYSE: BHC). The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with vertebrogenic radiculopathy.
Neuromultivit is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed to assess its effects in vertebrogenic radiculopathy.
Neuromultivit has one completed Phase 3 trial, NCT02508805, titled 'Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy.' The trial enrolled 100 participants in Russia and was active-controlled, though not double-blinded.
Neuromultivit is a distinct drug candidate developed by Bausch Health. No alternative names have been reported for this investigational therapy in the context of its clinical development for vertebrogenic radiculopathy.